$BRFH
BARFRESH FOOD GROUP INC.

2023 Q2 Form 10-Q Financial Statement

#000149315223013828 Filed on April 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $1.511M $2.091M $2.526M
YoY Change -46.02% -17.22% 148.9%
Cost Of Revenue $1.037M $1.236M $1.762M
YoY Change -45.88% -29.85% 164.75%
Gross Profit $474.0K $855.0K $764.0K
YoY Change -46.32% 11.91% 118.71%
Gross Profit Margin 31.37% 40.89% 30.25%
Selling, General & Admin $1.118M $1.661M $1.467M
YoY Change -25.62% 13.22% 114.64%
% of Gross Profit 235.86% 194.27% 192.02%
Research & Development $35.00K $21.00K $30.00K
YoY Change -63.92% -30.0% -55.97%
% of Gross Profit 7.38% 2.46% 3.93%
Depreciation & Amortization $87.00K $92.00K $161.0K
YoY Change -20.91% -42.86% 9.58%
% of Gross Profit 18.35% 10.76% 21.07%
Operating Expenses $1.216M $1.765M $1.658M
YoY Change -24.94% 6.45% 84.52%
Operating Profit -$742.0K -$910.0K -$894.0K
YoY Change 0.68% 1.79% 62.78%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$742.0K -$910.0K -$894.0K
YoY Change 0.68% 1.79% 51.14%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$742.0K -$910.0K -$894.0K
YoY Change 0.68% 1.79% 51.14%
Net Earnings / Revenue -49.11% -43.52% -35.39%
Basic Earnings Per Share -$0.06 -$0.07 -$0.07
Diluted Earnings Per Share -$0.06 -$0.07 -$69.22K
COMMON SHARES
Basic Shares Outstanding 13.00M shares 12.97M shares 12.91M shares
Diluted Shares Outstanding 13.00M shares 12.98M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $952.0K $1.566M $4.284M
YoY Change -73.05% -63.45% 117.49%
Cash & Equivalents $952.0K $1.566M $4.534M
Short-Term Investments
Other Short-Term Assets $99.00K $380.0K $351.8K
YoY Change -62.07% 8.02% 74.99%
Inventory $970.0K $1.055M $850.8K
Prepaid Expenses
Receivables $362.0K $571.0K $1.720M
Other Receivables $108.0K $11.00K $232.0K
Total Short-Term Assets $2.491M $3.583M $7.439M
YoY Change -63.13% -51.83% 111.71%
LONG-TERM ASSETS
Property, Plant & Equipment $627.0K $297.0K $1.527M
YoY Change -53.42% -80.55% -21.85%
Goodwill
YoY Change
Intangibles $275.0K $291.0K
YoY Change -18.88%
Long-Term Investments
YoY Change
Other Assets $7.000K $7.000K $6.750K
YoY Change 0.0% 3.7% -54.45%
Total Long-Term Assets $909.0K $595.0K $1.888M
YoY Change -47.91% -68.48% -20.81%
TOTAL ASSETS
Total Short-Term Assets $2.491M $3.583M $7.439M
Total Long-Term Assets $909.0K $595.0K $1.888M
Total Assets $3.400M $4.178M $9.326M
YoY Change -60.01% -55.2% 58.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $775.0K $1.306M $1.378M
YoY Change -39.31% -5.2% 309.17%
Accrued Expenses $340.0K $255.0K $502.4K
YoY Change 70.0% -49.24% -51.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.937M $2.333M $1.880M
YoY Change 9.99% 24.1% -46.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $33.60K
YoY Change -56.21%
Total Long-Term Liabilities $0.00 $0.00 $33.60K
YoY Change -100.0% -95.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.937M $2.333M $1.880M
Total Long-Term Liabilities $0.00 $0.00 $33.60K
Total Liabilities $1.937M $2.333M $1.914M
YoY Change 9.99% 21.92% -54.43%
SHAREHOLDERS EQUITY
Retained Earnings -$59.62M -$59.29M
YoY Change 10.82%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.463M $1.845M $7.413M
YoY Change
Total Liabilities & Shareholders Equity $3.400M $4.178M $9.326M
YoY Change -60.01% -55.2% 58.15%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$742.0K -$910.0K -$894.0K
YoY Change 0.68% 1.79% 51.14%
Depreciation, Depletion And Amortization $87.00K $92.00K $161.0K
YoY Change -20.91% -42.86% 9.58%
Cash From Operating Activities -$825.0K -$1.242M -$1.132M
YoY Change 4.32% 9.7% 187.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$13.52K
YoY Change -100.0% 128.76%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$13.52K
YoY Change -100.0% 128.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.000K
YoY Change -99.1%
NET CHANGE
Cash From Operating Activities -825.0K -$1.242M -1.132M
Cash From Investing Activities 0.000 -13.52K
Cash From Financing Activities 0.000 5.000K
Net Change In Cash -825.0K -$1.242M -1.141M
YoY Change 4.39% 8.88% -845.97%
FREE CASH FLOW
Cash From Operating Activities -$825.0K -$1.242M -$1.132M
Capital Expenditures $0.00 -$13.52K
Free Cash Flow -$825.0K -$1.242M -$1.119M
YoY Change 4.25% 11.03% 188.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001487197
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q1 BRFH Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards
ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41228
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BARFRESH FOOD GROUP INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1994406
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3600 Wilshire Blvd.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1720
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90010
CY2023Q1 dei City Area Code
CityAreaCode
310
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
598-7113
CY2023Q1 dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Not Applicable
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, $0.000001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
BRFH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
211000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
571000 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13002603 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1566000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2808000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
211000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2521000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126000 usd
CY2023Q1 us-gaap Other Receivables
OtherReceivables
11000 usd
CY2022Q4 us-gaap Other Receivables
OtherReceivables
101000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1055000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1048000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
169000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
79000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
3583000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
4373000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
297000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
389000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
291000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
306000 usd
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
7000 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
7000 usd
CY2023Q1 us-gaap Assets
Assets
4178000 usd
CY2022Q4 us-gaap Assets
Assets
5093000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1306000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1534000 usd
CY2023Q1 us-gaap Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current
AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent
499000 usd
CY2022Q4 us-gaap Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current
AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent
499000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
255000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
286000 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
273000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
233000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
20000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2333000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2572000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2333000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2572000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13002603 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13002603 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12934741 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12934741 shares
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61139000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60905000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59294000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58384000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1845000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2521000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4178000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5093000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2091000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2526000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1236000 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
1762000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
855000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
764000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
667000 usd
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
675000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
994000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
823000 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
104000 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
161000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1765000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1659000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-910000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-895000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12977000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12909000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-910000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-895000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
107000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
161000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
175000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
28000 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
83000 usd
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
98000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
445000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
497000 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-90000 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
232000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
145000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
92000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-228000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
404000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1242000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1132000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1242000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1141000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3019000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5675000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1777000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4534000 usd
CY2023Q1 BRFH Amounts Included In Measurement Of Lease Liabilities
AmountsIncludedInMeasurementOfLeaseLiabilities
20000 usd
CY2022Q1 BRFH Amounts Included In Measurement Of Lease Liabilities
AmountsIncludedInMeasurementOfLeaseLiabilities
20000 usd
CY2023Q1 BRFH Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards
ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards
24000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zMlHYDQwJwBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zTpGbqzH8gJ8">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zpEnplDfCFX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zqMmHJ15nWf1">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentrations in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfProductInformationTableTextBlock_zE3jbg9P4wZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zBwJcABVSR81" style="display: none">Schedule of Company’s Contract Manufacturers of Finished Goods</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zaZbeGttFrM6" style="width: 20%; text-align: right" title="Manufacturer percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zWSVKxddqP36" style="width: 20%; text-align: right" title="Manufacturer percentage">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zerZgBcLHdW1" style="text-align: right" title="Manufacturer percentage">46</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zbG2LRyNSxO9" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zL9VKvogjr9d" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zRl0OhYOp5Li" style="text-align: right" title="Manufacturer percentage">59</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A1_zk3UqiBbkab1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
211000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
211000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q1 BRFH Shipping And Handling Costs
ShippingAndHandlingCosts
311000 usd
CY2022Q1 BRFH Shipping And Handling Costs
ShippingAndHandlingCosts
386000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
49000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
65000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1006000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
983000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1055000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1048000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3706000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3706000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3409000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3317000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
297000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
389000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
92000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
145000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
4000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
0 usd
CY2023Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-03-31
CY2023Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extended through June 30, 2023
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
20000 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
20000 usd
CY2022 us-gaap Multiemployer Plan Increase In Employer Contribution Business Combination Percentage
MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage
0.52 pure
CY2021 us-gaap Multiemployer Plan Increase In Employer Contribution Business Combination Percentage
MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage
0.42 pure
CY2023Q1 us-gaap Legal Fees
LegalFees
100000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
8176000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
28000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
98000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-895000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7412000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2521000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
175000 usd
CY2023Q1 BRFH Adjustments To Additional Paid In Capital Cash Settlement Of Equitybased Compensation
AdjustmentsToAdditionalPaidInCapitalCashSettlementOfEquitybasedCompensation
-24000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-910000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1845000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1845000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
684639 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.85
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
227000 usd
CY2023Q1 BRFH Unrecognized Sharebased Compensation Weighted Average Period
UnrecognizedSharebasedCompensationWeightedAveragePeriod
P1Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
682939 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.30
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20891 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.62
CY2023Q1 BRFH Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.65
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
699830 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.14
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
638110 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.26
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y9M18D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.844 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.035 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.31
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
41923 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.92
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
5000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.25
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
4386 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.06
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4054 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.39
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
38483 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.37
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
24000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1242000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1777000 usd

Files In Submission

Name View Source Status
brfh-20230331_lab.xml Edgar Link unprocessable
0001493152-23-013828-index-headers.html Edgar Link pending
0001493152-23-013828-index.html Edgar Link pending
0001493152-23-013828.txt Edgar Link pending
0001493152-23-013828-xbrl.zip Edgar Link pending
brfh-20230331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
brfh-20230331_pre.xml Edgar Link unprocessable
brfh-20230331_cal.xml Edgar Link unprocessable
brfh-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending